Loading stock data…
Compass Therapeutics, Inc. (CMPX)
$2.16+0.08 (+3.85%)
Market ClosedLast close Jun 29
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Compass Therapeutics, Inc. in the Healthcare sector is trading at $2.16 with a market capitalization of $378M. Wall Street consensus targets $8.82 (11 analysts), implying a +308.2% move over the next 12 months. The stock is currently near its 52-week low of $1.61, remaining 50.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +308.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$20.30M↓ | -$17.99M↓ | -$15.82M↑ | -$21.07M↓ | -$17.97M |
| Net Income | -$18.32M↓ | -$15.72M↓ | -$14.26M↑ | -$19.88M↓ | -$16.63M |
Peer Comparison
JNJUNHPFE
Fundamentals
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bisp...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$378.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.56%
Volume
Today's trading volume
2.81M
Recent News
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story is tovecimig, an experimental cancer treatment being developed for biliary tract cancer, which affects the bile ducts, gallbladder, or nearby digestive organs. In its May 5 first-quarter update, Compass said tovecimig had received FDA Orphan […]
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secon
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M
Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best NASDAQ stocks under $5 to buy right now. On May 5, Compass Therapeutics reported a Q1 2026 net loss of $18.3 million, or $0.10 per share. R&D expenses rose to $13.4 million, while G&A expenses climbed 41% to $6.9 million due to stock compensation and $1.0 […]
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)
Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Day Trading Penny Stocks to Buy. On April 28, 2026, Canaccord lowered its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 from $13 and maintained a Buy rating. The firm said Tovecimig+paclitaxel showed improved progression-free survival versus paclitaxel monotherapy, but noted that 54% crossover […]
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?
Compass Therapeutics recently reported that its Phase 2/3 COMPANION-002 trial in previously treated advanced biliary tract cancer met the primary endpoint, with tovecimig plus paclitaxel achieving higher response rates and longer median progression-free survival than paclitaxel alone, while maintaining a safety profile consistent with earlier studies. An interesting insight from the data is that patients who crossed over from paclitaxel alone to the tovecimig combination, despite initially...